Abstract:Enterovirus 71 (EV71)–associated hand-foot-mouth disease has become a major threat to public health in the Asia–Pacific region. Although T cell immunity is closely correlated with clinical outcomes of EV71 infection, little is known about T cell immunity baseline against EV71 and T cell immunogenecity of EV71 Ags in the population, which has restricted our understanding of immunoprotection mechanisms. In this study, we investigated the cellular immune responses against the four structural Ags of EV71 and determined the immunohierarchy of these Ags in healthy adults. A low frequency of EV71-responsive T cells was detected circulating in peripheral blood, and broad T cell immune responses could be identified in most of the subjects after in vitro expansion. We demonstrated that the VP2 Ag with broad distribution of immunogenic peptides dominates T cell responses against EV71 compared with VP1, VP3, and VP4. Furthermore, the responses were illuminated to be mainly single IFN-g– secreting CD4 + T cell dependent, indicating the previous natural acute viral infection of the adult population. Conservancy analysis of the immunogenic peptides revealed that moderately variant peptides were in the majority in coxsackievirus A16 (CV-A16) whereas most of the peptides were highly variant in polioviruses. Less efficient cross-reactivity against CV-A16 might broadly exist among individuals, whereas influences derived from poliovirus vaccination would be limited. Our findings suggest that the significance of VP2 Ag should be addressed in the future EV71-responsive immunological investigations. And the findings concerning the less efficient cross-reactivity against CV-A16 and limited influences from poliovirus vaccination in EV71-contacted population would contribute to a better understanding of immunoprotection mechanisms against enteroviruses. S ince its first identification in California in 1969, enterovirus 71 (EV71)–associated hand-foot-mouth disease (HFMD) epidemics have been reported throughout the world, with large outbreaks mainly occurring in the Asia–Pacific region since 1990s (1–7). Although EV71 and coxsackievirus A16 (CV-A16) are the most common causative agents of HFMD, infection by EV71 usually carries a higher risk of developing central nervous complications and fatalities (8). In 2008, a nationwide EV71 outbreak started in Fuyang City, China, has caused ∼5000 cases and .188 deaths in mainland China (9). During the following years, .1 million incidences and hundreds of deaths have been reported annually in China, and EV71 has become a major threat to public health (http:// In the first half of 2012, the so-called " mystery disease " in children that caused .50 deaths in Cambodia was also found to …

EV71 Virus-Like Particles Produced by Co-Expression of Capsid Proteins in Yeast Cells Elicit Humoral Protective Response Against EV71 Lethal Challenge

EV71: an Emerging Infectious Disease Vaccine Target in the Far East?

Expression and Immunogenicity of Novel Subunit Enterovirus 71 Vp1 Antigens

Determinants of EV71 immunogenicity and protection against lethal challenge in a mouse model

A Broadly Cross-protective Vaccine Presenting the Neighboring Epitopes Within the VP1 GH Loop and VP2 EF Loop of Enterovirus 71

Development and characterization of an enterovirus 71 (EV71) virus-like particles (VLPs) vaccine produced in Pichia pastoris

Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice

Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop.

Progress of severe hand-foot-mouth disease infected by EV71 virus

Enterovirus A71 Vaccines

Research Progress of Enterovirus 71 Vaccines

Discovery of Potent EV71 Capsid Inhibitors for Treatment of HFMD

Characterization of Human Enterovirus71 Virus-Like Particles Used for Vaccine Antigens

Recombinant VP1 protein expressed in Pichia pastoris induces protective immune responses against EV71 in mice

Enterovirus 71 vaccine: close but still far

Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses

This information is current as in a Healthy Population against Coxsackievirus A 16 and Polioviruses against Enterovirus 71 and Cross-Reactivity T Cell Responses + VP 2 Dominated CD 4

EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD)

Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine

SLC35B2 Acts in a Dual Role in the Host Sulfation Required for EV71 Infection

Characterization of the Enterovirus 71 P1 Polyprotein Expressed Inpichia Pastoras a Candidate Vaccine